Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PRE-Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis: A Phase I/II Platform Trial

NCT05868226 is registered in ClinicalTrials.gov with QuantumLeap Healthcare Collaborative as lead sponsor.

NCT NCT05868226
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05868226 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PRE-Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis: A Phase I/II Platform Trial
Lead sponsor
QuantumLeap Healthcare Collaborative
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 15, 2023
Completion date
December 30, 2031
Enrollment
280 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma, adenocarcinoma of colon, colo-rectal cancer, colon cancer, colonic neoplasms, colorectal neoplasms, ctdna monitoring, er positive breast cancer, estrogen receptor positive tumor, her-2 protein overexpression, her2 low breast cancer, her2 low breast carcinoma, her2 mutation-related tumors, her2-negative breast cancer, her2-positive breast cancer, her2-positive metastatic breast cancer, hormone receptor negative breast carcinoma, hormone receptor-positive breast cancer, hr positive, metastatic, metastatic breast cancer, metastatic cancer, minimal residual disease, neoplasm, residual, pr-positive breast cancer, progesterone receptor-positive breast cancer, rectal cancer, rectal neoplasms, solid carcinoma, solid tumor, solid tumor, adult, triple negative breast cancer